Receive our newsletter – data, insights and analysis delivered to you
  1. Adare Pharmaceuticals
14 February 2013

Aptalis Pharmaceutical Technologies Expands Licensing Team

Aptalis Pharmaceutical Technologies, a business unit of Aptalis Pharma that develops differentiated products utilizing its oral delivery technologies, today announces that Nigel Ray has been named as the company’s Vice President of Global Licensing.

Reporting to John Fraher, President of Aptalis Pharma, Mr. Ray will lead the unit’s global licensing efforts as well as the identification and evaluation of strategic opportunities within the pharmaceutical industry that maximize the value of Aptalis’ technologies. Prior to joining Aptalis, during his twenty-five years in specialty pharmaceuticals, Mr. Ray held executive-level positions with companies including AcelRx Pharmaceuticals, DURECT Corporation and Alza Corporation. Mr. Ray holds a Bachelor of Arts in Human Biology from Stanford University and a Master of Business Administration, Finance and Strategy from the UCLA Anderson School of Management.

"Nigel’s rich experience in identifying, structuring and negotiating complex, worldwide product licensing transactions, as well as his business leadership skills, will serve Aptalis well," said Mr Fraher. "His leadership and experience in business development and marketing will enable the expansion of our technology partnerships while providing pharmaceutical companies with the drug delivery solutions they need to advance and protect product portfolios," added Mr Fraher.

Dysphagia can affect many people throughout their lifetime and may compromise medication adherence.
For pharmaceutical manufacturers and healthcare providers, non-adherence to medication is a significant concern.
NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU